A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumours
This rollover study is designed to provide continued access to GSK2118436 for eligible
subjects with BRAF mutation-positive tumours who have previously participated in a
GlaxoSmithKline (GSK)-sponsored GSK2118436 study (parent study), who have no evidence of
progressive disease and who have tolerated GSK2118436 in the parent study without
significant toxicities. Subjects will be enrolled into the appropriate cohort based upon the
treatment received in their parent study. Safety assessments (physical examinations, vital
signs, 12-lead electrocardiograms, echocardiograms, clinical laboratory assessments, and
monitoring of adverse events) will be made throughout the study. Clinical activity will be
assessed using local standard of care imaging practices and the appropriate response
criteria as determined by the investigator.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society